New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+channel blocker
Authors:
- Alan H GradmanAGAlan H Gradman
- Yoel VivasYVYoel Vivas
- 22 August 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 16 (9) , 1449-1457
Abstract
Intravenous antihypertensive agents are used in clinical situations in which the immediate, precise control of blood pressure is a clinical necessity. Clevidipine is a new, vascular-selective, dihyrdopyridine Ca2+ channel blocker, which exerts its hemodynamic effects through selective arterial vasodilation without effects on the venous circulation. Because it is a potent coronary vasodilator, reduction in mean arterial pressure does not impair coronary perfusion. The unique properties of clevidipine include an ultra-short pharmacodynamic duration of action and a half-life after intravenous administration of ∼ 2 min, resulting in very rapid onset and offset of antihypertensive effects. In clinical trials performed in patients undergoing cardiac surgery, clevidipine proved superior to nitroprusside and nitroglycerin in maintaining blood pressure within predetermined ranges during the perioperative period. Its safety profile is comparable to nicardipine and nitroglycerin and, in one study, was associated wit...Keywords
This publication has 27 references indexed in Scilit:
- Vascular Disease, Hypertension and PreventionJACC, 2007
- Intravenous NicardipineDrugs, 2006
- Pharmacodynamic, Pharmacokinetic and Clinical Effects of Clevidipine, an Ultrashort‐Acting Calcium Antagonist for Rapid Blood Pressure ControlCardiovascular Drug Reviews, 2004
- Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgeryEuropean Journal of Anaesthesiology, 2003
- Guidelines for the Early Management of Patients With Ischemic StrokeStroke, 2003
- Clevidipine in Adult Cardiac Surgical PatientsAnesthesiology, 2002
- EFFECTS OF FENOLDOPAM, A DOPAMINE D-1 AGONIST, AND CLEVIDIPINE, A CALCIUM CHANNEL ANTAGONIST, IN ACUTE RENAL FAILURE IN ANESTHETIZED RATSClinical and Experimental Hypertension, 2002
- Clinical and pharmacokinetic results with a new ultrashort‐acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteersBritish Journal of Clinical Pharmacology, 1999
- Predictors of postoperative myocardial ischaemia The role of intercurrent arterial hypertension and other cardiovascular risk factorsAnaesthesia, 1997
- Selectivity Scale of Calcium Antagonists in the Human Cardiovascular System Based on In Vitro StudiesJournal of Cardiovascular Pharmacology, 1992